SAGE PRO

Home / Research / Neuland Laboratories Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Neuland Laboratories Limited — Q2 FY27 Results Analysis

WATCH: attractive franchise, demanding valuation

Published · Quarter Q2 FY27 · NEULANDLAB

Price₹21,640
FY26 P/E76.3x
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Q2 shipment moderation

Q2 FY26₹514.27 cr
Q1 FY27₹641.58 cr
Q2 FY27₹449.66 cr

Issuer Q2 statutory results / presentation / analyst calculations

CHART 2

H1 +35.2%

H1 FY26₹807.03 cr
H1 FY27₹1,091.23 cr

Issuer Q2 statutory results / presentation / analyst calculations

CHART 3

Commercial supply drives growth

Prior commercial₹411 cr
Current commercial₹639 cr
Prior development₹32 cr
Current development₹41 cr

Issuer Q2 statutory results / presentation / analyst calculations

CHART 4

99 active projects

Preclinical17 count
Phase I23 count
Phase II20 count
Phase III13 count
Pre-reg/reg7 count
Commercial19 count

Issuer Q2 statutory results / presentation / analyst calculations

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

WATCH: attractive franchise, demanding valuation

H1 strong, Q2 weaker

Watch: Require repeat commercial cash

RESEARCH INSIGHT

Q2 shipment moderation

Consolidated operating sales

Watch: Track cumulative revenue

RESEARCH INSIGHT

H1 +35.2%

Q1 strength offsets weaker Q2

Watch: Verify H2

RESEARCH INSIGHT

Commercial supply drives growth

Management business-mix disclosure

Watch: Track repeat volume

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

SAGE PRO Institutional Research | 16 November 2026 | Q2 FY2027 | NSE: NEULANDLAB

1. Investment decision and variant thesis

Key takeaways

  • WATCH — differentiated manufacturing franchise, demanding valuation and uneven commercial shipments. Q2 consolidated operating revenue ₹449.66 crore fell 12.6% YoY and 29.9% QoQ, with PAT ₹51.63 crore down 46.7% YoY.
  • H1 revenue ₹1,091.23 crore rose 35.2%, while PAT ₹199.30 crore rose 79.9%.
  • This is a business whose commercial custom manufacturing orders vary materially by molecule and shipment period.

Assess cumulative sales, cash and asset returns rather than extrapolating either Q1's peak or Q2's trough. The business is moving from ordinary generic API economics toward complex, customer-specific commercial manufacturing.

Reference ₹21,640, Sage PRO financial data quote observed 16 November 2026 around 16:31 IST (not an independently certified settlement price). Paid-up equity ₹12.9005 crore at ₹10 face value implies 1.29005 crore issued shares and equity value approximately ₹27,917 crore.

FY26 consolidated EPS ₹283.71 implies 76.3x; annualised H1 EPS ₹310.68 implies 69.7x, not a forecast. Our illustrative FY28 base EPS ₹418.27 at 50x gives ₹20,913. The company can grow strongly and still deliver modest stock returns if valuation normalises.

The 12–24 month stance improves with sustained commercial demand, healthy owner cash and demonstrable productive capacity returns, or a more favourable entry price.

Variant thesis: commercial CMS growth and the late-stage pipeline provide a credible route to higher earnings, while modular peptide manufacturing creates longer-duration optionality. The counter-thesis is customer concentration, variable shipment quantities, input inflation and idle new assets before customer qualification.

Management says H1 was broadly on plan and FY27/FY28 growth expectations remain intact, not a specific quantitative forecast in the reviewed excerpt. The fundamental thesis fails if scientific capability and new capital persistently do not translate into repeat commercial cash.

This original source-verified research uses the Q2 statutory filing, accepted presentation and call; independent full institutional QA remains outstanding.

2. Business economics and commercial pipeline

Key takeaways

  • CMS develops and manufactures APIs/intermediates for pharmaceutical innovators; generic drug substances (GDS) supply non-exclusive APIs.
  • Prime includes Ezetimibe and Mirtazapine; specialty includes Deferasirox, Apixaban and Donepezil.
  • Two DMFs for Fezolinetant and Ivacaftor expand the development portfolio, but filing is not approval or guaranteed sales.

GDS supports scale and diversification, with different price and material-cost economics. CMS offers process-specific differentiation and qualification advantages; the customer still controls the drug, clinical outcome, launch and allocation. A qualified relationship can be sticky without being exclusive or indefinitely secure.

The September deck discloses 99 active CMS projects versus 98 a year earlier: 17 preclinical, 23 Phase I, 20 Phase II, 13 Phase III, seven pre-registration/registration and 19 commercial (nine APIs, ten intermediates). Prior-year Phase III was eight and commercial 18.

The stage progression is more meaningful than a nearly flat total count. Pre-registration may include second-source qualification for a marketed drug. Counts do not reveal commercial contract value, margin, clinical probability or launch timing.

A low-volume ophthalmic intermediate ordered intermittently and a large API programme are economically very different. Do not value each molecule equally.

CMS management metricsH1 FY26H1 FY27
Commercial revenue, ₹cr411639
Development revenue, ₹cr3241
Total of disclosed categories, ₹cr443680

These are management business-mix disclosures, not independently audited segment profits. The Q2 commercial amount was about ₹214 crore and development ₹32 crore. Management said five or six commercial molecules contributed revenue in Q2, with some smaller intermediates ordered only every few years.

The call indicated no new launch in the preceding two or three quarters; differing order quantities drove recent unevenness rather than a new launch spike followed by disappearance. This is a testable explanation, not assurance of future shipments.

Evaluate aggregate repeat demand, customer conversion, new awards and net attrition over a longer period.

Peptide manufacturing and the cost of waiting

The first peptide module at Unit I is commissioned. Management describes upstream solid/liquid-phase synthesis and downstream purification and isolation, including purification columns and lyophilisation or spray drying. Neuland aims to make finished peptide API, not merely fragments. Module 1 is designed around two projects currently progressing. Equipment size must match batch requirements; oversized columns or reactors can force uneconomic output. Additional modules are to be based on actual demand and project fit, not a generic market size. Development, process qualification and commercial supply are separate milestones. The reviewed evidence does not identify a specific GLP-1 award or undisclosed commercial peptide revenue.

The most important Q&A disclosure is that Neuland bears idle costs for general portfolio capacity, except where a customer-specific facility arrangement changes the economics. Management anticipates some idle time over 1–1.5 years.

Development billings exist but are small; PPQ (process performance qualification) or validation-related revenue is expected around six to nine months from the call. A commercial supply agreement depends on successful validation, customer progress and applicable regulatory milestones.

Modules 2–4 depend on occupancy and visible projects. Do not treat a commissioned facility as mature utilised capacity. Track validated batches, yield, throughput, committed orders, actual capital spend and cash.

3. Consolidated statutory financial analysis

Key takeaways

  • Amounts in ₹ crore except EPS; statutory ₹ lakh figures divided by 100.
  • The issuer presentation mainly uses standalone total income and EBITDA, whereas this table uses consolidated statutory operating sales.
  • Rounding may cause minor differences.
MetricQ2 FY27Q1 FY27Q2 FY26H1 FY27H1 FY26FY26
Operating revenue449.66641.58514.271091.23807.032022.99
Other income7.508.491.8015.999.6630.17
Total income457.15650.07516.071107.22816.682053.15
Materials + inventory change151.06221.02183.61372.08297.15755.50
Employee expense101.76106.4380.37208.19153.84341.14
Manufacturing expense57.8047.9445.96105.7485.33191.61
Other expense41.4843.3048.7984.7780.67160.23
Derived operating EBITDA97.56222.89155.55320.45190.03574.50
D&A28.7726.5622.5455.3342.7391.74
Finance cost7.316.975.3714.289.9523.95
PBT68.98197.85129.44266.83147.01488.98
PAT51.63147.6796.85199.30110.75364.00
Basic/diluted EPS ₹40.24115.1075.49155.3486.32283.71

Q2 operating EBITDA ₹97.56 crore equals operating sales less materials/inventory, employee, manufacturing and other expenses. Add other income ₹7.50 crore and subtract D&A ₹28.77 crore and interest ₹7.31 crore to reach PBT ₹68.98 crore; tax ₹17.35 crore gives PAT ₹51.63 crore.

The issuer's standalone Q2 EBITDA ₹104.55 crore, margin 22.9% of total income, and PAT ₹51.13 crore are distinct. H1 standalone EBITDA ₹335.62 crore at 30.3% versus ₹199.07 crore/24.4%. Consolidated derived operating EBITDA Q2 ₹97.56 crore (21.7%) versus ₹155.55 crore (30.2%); H1 ₹320.45 crore (29.4%) vs ₹190.03 crore (23.5%).

Both measures show strong H1 and weaker Q2; maintain consistent scope and denominators.

Operating deleverage

Sequential sales fell ₹191.92 crore. Materials/inventory costs fell ₹69.96 crore, personnel ₹4.67 crore, manufacturing expense rose ₹9.86 crore and other expense fell ₹1.82 crore. EBITDA fell ₹125.33 crore, about 65% of lost sales. This is fixed-resource and mix deleverage, not a permanent decremental margin. YoY sales fell ₹64.62 crore while employee and manufacturing expenses rose ₹21.39 crore and ₹11.85 crore; materials/inventory fell ₹32.55 crore and other expense fell ₹7.31 crore. EBITDA declined ₹57.99 crore. Q2 inventory-change credit ₹64.73 crore versus ₹44.03 crore prior year and ₹7.75 crore Q1. Combined material/inventory cost 33.6% of sales versus 35.7% prior year. The improvement did not offset lower revenue and overhead; inventory credits are not necessarily cash savings.

H1 sales rose ₹284.21 crore (+35.2%), EBITDA ₹130.42 crore (+68.6%), PAT ₹88.54 crore (+79.9%). Tax ₹67.53 crore on PBT ₹266.83 crore gives 25.3%, a reasonable forward assumption. Employee costs increased ₹54.35 crore, manufacturing ₹20.41 crore and D&A ₹12.60 crore.

Strong H1 absorption supports the franchise but Q2 shows the cost of underutilisation. FY26 derived operating EBITDA ₹574.50 crore (28.4%), EBIT ₹482.76 crore and PAT ₹364 crore. H1 other income ₹15.99 crore versus ₹9.66 crore is excluded from core operating margin.

FY26 operating sales ₹2,022.99 crore, H2 ₹1,215.96 crore. FY27 H1 ₹1,091.23 crore. Flat FY27 requires ₹931.75 crore H2 (-23.4% YoY); 20% annual growth requires ₹1,336.35 crore (+9.9%); 30% requires ₹1,538.65 crore (+26.5%).

Repeating Q2 twice produces annual sales ₹1,990.55 crore (-1.6%). The strong first half does not establish a specific full-year growth rate. These analyst hurdles are reproducible and should be updated after Q3; do not mistake the issuer's qualitative growth expectation for guidance on a precise percentage.

4. Cash, balance sheet and capital returns

Key takeaways

  • H1 consolidated CFO ₹361.56 crore versus negative ₹36.75 crore prior H1.
  • Pre-working-capital operating cash ₹319.52 crore vs ₹198.42 crore.
  • Receivables released ₹246.09 crore versus prior-year use ₹123.19 crore; inventory consumed ₹41.81 crore and payables consumed ₹58.74 crore.

Taxes paid ₹72.86 crore. CFO/PAT ~181%; strong underlying earnings and collections both contributed, but a large release from high opening receivables should not be extrapolated as perpetual cash. The proper owner-return test uses rolling operating cash, working capital and productive asset investment.

H1 consolidated cash flow ₹crFY27FY26
Operating cash before working capital319.52198.42
Inventory movement-41.81-162.14
Receivables movement246.09-123.19
Payables movement-58.7434.05
Cash before taxes434.423.18
Tax paid-72.86-39.92
CFO361.56-36.75
Physical capital purchases260.60170.75
CFO less capital purchases100.96-207.50

Balance sheet and funding

September assets ₹3,029.56 crore vs March ₹2,930.14 crore; equity ₹2,029.71 crore vs ₹1,874.47 crore. PPE ₹901.62 crore vs ₹793.42 crore; CWIP ₹284.30 crore vs ₹209.50 crore; goodwill ₹279.46 crore unchanged; ROU ₹92.58 crore. PPE+CWIP rose ₹183 crore to ₹1,185.92 crore. Inventory ₹552.10 crore vs ₹510.29 crore, receivables ₹294.30 vs ₹541.35 crore, payables ₹208.62 vs ₹269.14 crore. Narrow trade working capital fell ₹782.50 to ₹637.78 crore. Management standalone working capital ₹628.5 crore and days 104 vs 155 prior H1, but 84 in Q1. Definitions differ; collection improved while inventory and supplier payments still require capital. Ending receivables roughly 49 days of annualised H1 sales versus ~98 days at March/FY26 sales, not contractual DSO.

Borrowings ₹239.20 crore vs ₹196.61 crore March; lease liabilities ₹103.10 crore. Cash equivalents ₹53.66 crore plus other bank balances ₹396.78 crore = ₹450.44 crore; less borrowings gives broad net cash ₹211.24 crore before restrictions and leases.

Management standalone net cash ₹208 crore versus ₹308.5 crore Q1 and ₹156.8 crore March. Measures are close, not identical. Narrow debt less cash ₹185.54 crore. Current assets ₹1,389.85 crore/current liabilities ₹618.58 crore = 2.25x vs 2.09x March.

Other bank balances require unrestricted liquidity reconciliation. Do not add net cash to an equity earnings valuation that already includes financial income.

Productive capital versus land optionality

Module 1 commissioned, Genome Valley process R&D expected fully operational by early next year, ~134 acres acquired at Kakinada for long-term capacity. The November board separately approved ₹47.1 crore including GST and related expense for six acres at Domadugu through internal accruals; no capacity or commencement date disclosed. Land purchase, construction, qualification, PPQ, customer orders and collected cash are separate milestones. Management indicated Kakinada could be slowed if commercial demand weakens; later peptide modules depend on occupancy and project visibility. Cash-rich funding is helpful but no guarantee of incremental return.

An illustrative ₹300 crore productive investment at 15% after-tax return needs ₹45 crore NOPAT or ₹60 crore EBIT at 25% tax. With ₹20–30 crore incremental D&A, ₹80–90 crore EBITDA requires ₹267–300 crore annual sales at 30% operating margin.

Not a disclosed project cost or forecast. FY26 EBIT ₹482.76 crore / September PPE+CWIP ₹1,185.92 crore is a rough 40.7% pre-tax asset-return proxy; annualised H1 EBIT ₹530.24 crore gives 44.7%. Neither is full ROCE because working capital, goodwill, leases, average capital and financial assets differ.

Historical asset absorption is strong; idle peptide assets and land can depress future return until customer output follows.

5. Management execution and observable milestones

Key takeaways

  • Peptide economics are explicit: small development revenue now, PPQ-related revenue expected around six to nine months, then successful validation and customer-dependent supply.
  • Idle costs remain with Neuland for portfolio capacity; expected idle periods of 1–1.5 years matter to forward margins.
  • Additional modules must follow actual qualification and occupancy.

RFP activity described as strongest to date and large-pharma traction improve opportunity but are not booked sales. Diversification is demonstrated through repeat revenue from new customers.

6. Valuation, reverse expectations and FY28 scenarios

Key takeaways

  • At ₹21,640 and 1.29005 crore issued shares, equity value ~₹27,917 crore.
  • FY26 PAT ₹364 crore implies 76.7x using current shares; EPS ₹283.71 gives 76.3x because weighted-average shares differ.
  • Narrow EV = equity + ₹239.20 crore borrowing − ₹53.66 crore cash = ~₹28,102 crore, excluding leases and other bank balances.

FY26 derived EBITDA ₹574.50 crore implies 48.9x narrow EV/EBITDA; not a full comparable EV. Model 1.30 crore shares, consolidated earnings, operating margin and explicit D&A, interest and tax assumptions.

FY28 analyst scenario (₹cr except EPS/price)BearBaseBull
Operating sales230030003800
Operating EBITDA margin21%30%34%
Operating EBITDA4839001292
Other income253035
D&A150170190
Finance cost353540
PBT3237251097
PAT at 25% tax242.25543.75822.75
EPS on 1.30cr shares186.35418.27632.88
Terminal P/E assumption35x50x60x
Indicative price ₹65222091337973
Change vs reference-70%-3%+75%

Bear assumes slower commercial deliveries, underutilised new assets and margin compression. Base assumes FY26–FY28 sales CAGR ~21.8%, margin 30% near H1, and higher D&A. Bull assumes ~37% sales CAGR, 34% margin and successful customer conversion.

These are independent analyst cases, not guidance, consensus or probability-weighted price targets; dividends and discounting excluded. Base PAT ~₹544 crore is 49% above FY26 yet indicative price below reference at 50x.

At 40x base EPS gives ₹16,731, at 60x ₹25,096. Strong business growth alone is insufficient at a premium valuation.

Reverse valuation at 50x: ₹21,640 requires EPS ₹432.80, PAT ₹562.64 crore on 1.30 crore shares. At 25% tax PBT ₹750.19 crore. Add D&A ₹170 crore, interest ₹35 crore and subtract other income ₹30 crore: EBITDA needed ₹925.19 crore.

At 30% margin sales ₹3,084 crore, ~23.5% CAGR from FY26 over two years. At 25% margin required sales ₹3,701 crore; at 35% ₹2,643 crore. For 20% price upside at 50x, EPS ₹519.36, PAT ₹675.17 crore, PBT ₹900.23 crore, EBITDA ₹1,075.23 crore and sales ₹3,584 crore at 30%.

A lower entry price changes the required growth without changing business quality.

Sensitivity: EPS ₹300 at 35x/50x/60x gives ₹10,500/15,000/18,000; ₹450 EPS gives ₹15,750/22,500/27,000; ₹600 gives ₹21,000/30,000/36,000. Each additional ₹100 crore revenue at 30% incremental EBITDA and 25% tax adds ₹22.5 crore PAT before extra D&A/interest, ~₹17.31 EPS or ₹865 at 50x.

Not a linear forecast for a large capacity expansion. A full owner-cash DCF needs project-specific capex, clinical and qualification probabilities, future working capital, tax and reinvestment. H1 collection release is not perpetual cash yield.

No unverified peer multiple or precise DCF target is asserted.

7. Risks, catalysts and original evidence

Catalysts: cumulative H2 CMS deliveries, net late-stage and commercial conversion, diversification, PPQ-related peptide revenue and subsequent supply, Genome Valley operation, healthy normalised operating margin and rolling cash. Risks: customer/molecule concentration, shipment timing, clinical failure and sourcing shifts, patent/competition, raw materials/freight, quality and regulatory compliance, idle peptide cost, excessive land/plant investment, working-capital reversals, valuation compression. Follow official inspection outcomes; lack of adverse news is not proof of compliance.

Track operating EBITDA, CFO before working capital, physical capital purchases, debt/deposits, commercial contribution and EPS. A sustained gap between scientific capability and owner cash invalidates the constructive thesis.

Revisit WATCH on stronger evidence or a better entry price.

Original source ledger.

Key takeaways

  • S1. 3 November 2026 board outcome, consolidated and standalone results, balance sheet, cash flow and limited review: https://nsearchives.nseindia.com/corporate/NEULANDLAB_03112026154657_SEOutcome_03112026.pdf .
  • Statutory ₹ lakh converted to ₹ crore.
  • Original table text accessible; screenshot retrieval failed, so page-image parity not certified.

Board land approval ₹47.1 crore.

S2. Q2 FY27 investor presentation, 3 November: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e485402-d792-49dd-810e-4e0141fd33ed.pdf . Canonical 69651, current semantic ACCEPT. Pages 6–11 for financial highlights, CMS funnel, mix and operating metrics; overview for capability data.

S3. Call held 3 November, filed 6 November: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=abfcdee9-1e06-45b7-a6ab-8d7490dfebef.pdf . Canonical 76405, current semantic ACCEPT. Q&A pp. 5–10 peptide idle costs, PPQ timing, shipment pattern, concentration and patent commentary.

S4. Issuer Q2 release: . S5. Sage PRO financial data quote ₹21,640 observed 16 November 2026 ~16:31 IST; refresh before investing.

Independent full institutional QA, original page-image parity, quantified peer valuation, complete owner-cash DCF and project-level return/patent reconciliation remain outstanding. Forward inputs and thresholds are analyst assumptions. This is a source-verified original longform, not a certified full-QA edition.

Additional company evidence

CHART 5

Phase III up from eight to 13

Prior Phase III8 count
Current Phase III13 count
Prior commercial18 count
Current commercial19 count

Issuer Q2 statutory results / presentation / analyst calculations

CHART 6

Europe/North America grew

India₹161.49 cr
Europe₹503.56 cr
North America₹328.55 cr
Other₹97.64 cr

Issuer Q2 statutory results / presentation / analyst calculations

CHART 7

Q2 deleverage

Q2 FY26₹155.55 cr
Q1 FY27₹222.89 cr
Q2 FY27₹97.56 cr

Issuer Q2 statutory results / presentation / analyst calculations

CHART 8

Different scope and denominator

Prior Q2 operating30.2%
Q1 operating34.7%
Q2 operating21.7%
Q2 deck22.9%

Issuer Q2 statutory results / presentation / analyst calculations

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Q2 statutory results
  2. Q2 investor presentation
  3. Q2 earnings call

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.